Health · 49 views
New T-cell engager shows promise for advanced solid tumors
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors.
Summary
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell engager (TCER) that specifically links cancer cells with T cells, thereby directly activating the immune system to fight the tumor.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- 'Medicare for All' message attracts midterm voters buckling under medical billsContinue reading
- Abnormal lymph vessels show heightened growth signaling regardless of key gene mutationContinue reading
- Pausing certain arthritis drugs after COVID-19 vaccination raises flare risk without improving antibody responseContinue reading
- CDC funding for HIV prevention shifted from providers to states under TrumpContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow